Julien Nono-Womdim’s Top Picks for Nov. 18, 2026
Summary
- Julien Nono-Womdim, Vice President of Equity Analysis at Goodreid Investment Counsel, identifies TG Therapeutics, Medpace Holdings, & United Natural Foods as top U.S. equity picks.
- The Nasdaq 100 has dropped over 10% from its October high, while over 50% of S&P 500 members are down 20% or more from record highs.
- Stock repricing is driven by higher interest rates, geopolitical uncertainty in the Middle East & Europe, & risks regarding AI spending returns.
- S&P 500 profits are projected to grow by approximately one-third this year & mid-teens next year, with the index trading at 18 times forward earnings.
- Technology sector growth is expected to remain led by AI spending, supported by favorable corporate returns & government priority on domestic AI.
- The bear case warns that elevated inflation & potential Fed rate hikes could weaken consumer spending, potentially spiraling into industrial earnings misses.
- TG Therapeutics (TGTX) is a commercial-stage biotech with its MS drug BRIUMVI crossing $1 billion in annualized sales, with peak sales projected at $5 billion by the early 2030s.
- Medpace Holdings (MEDP) is a clinical research organization benefiting from structural shifts to outsourced models & a cyclical recovery in biopharma R&D.
- United Natural Foods (UNFI) is a wholesale food distributor viewed as recession-resistant, generating ~$300 million in annual free cash flow at 10 times FCF.
- Past picks from February 10, 2026, include Merck with a 23% total return, Citigroup with a -0.3% total return, & Celestica with a -18% total return.
Top Picks from Julien Nono-Womdim, Vice President, Equity Analysis, Goodreid Investment Counsel